HALO vs BMRN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HALO · Halozyme Therapeutics$91.35 ▼ 1.82%
BMRN · Biomarin Pharmaceutical$60.41 ▼ 1.64%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HALO +23.4%
- BMRN +8.8%
Head to head
| Metric | HALO | BMRN |
|---|---|---|
| Price | $91.35 | $60.41 |
| Change today | ▼ 1.82% | ▼ 1.64% |
| Market cap | $10.41B | $11.70B |
| Return, 3 months | -15.9% | -7.2% |
| Return, year to date | +35.7% | +1.6% |
| Return, 1 year | +29.9% | +10.5% |
| P/E (TTM) | 22.8 | – |
| P/B | -188.4 | 1.9 |
| P/E percentile vs own 5y | 65th | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +39.2% | +32.0% |
| Net profit growth (YoY) | +41.0% | -299.5% |
| Gross margin | 82.3% | 76.0% |
| Operating margin | 55.9% | 4.9% |
| Net margin | 26.9% | -0.5% |
| Return on equity | 216.4% | -0.3% |
| Analyst target vs. price | +37.5% | +46.9% |
| Analyst buy share | 80% | 74% |
| RSI (14) | 20 | 59 |
| 30-day volatility | 60.1% | 31.8% |
| Max drawdown, 1 year | -30.4% | -22.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BMRN is the largest of the group by market value.
- HALO has returned the most over the past year.
- HALO is growing revenue fastest.
- HALO keeps the most profit per dollar of sales.
- BMRN has been the calmest stock over the last 30 days.